Clinical Trials Logo
  1. Home
  2. Retinal Vein Occlusion
  3. NCT06416241

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion — INTRAMED-CRVO  

Retinal Vein Occlusion Clinical Trial

Official title:
Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

Clinical Trial Summary

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder, occurring when there is a blockage to the main blood vessel that transports blood away from the retina. CRVO may cause visual impairment, especially due to macular edema (swelling of the macula due to fluid accumulation) and macular non-perfusion. Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials. The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world, using a patient-fitted treatment regimen. Additionally, imaging parameters have been assessed before and after treatment with intravitreal aflibercept.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06416241
Study type Interventional
Source University of Athens
Contact
Status Completed
Phase Phase 4
Start date January 1, 2017
Completion date March 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT04592419 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 3
Recruiting NCT05133791 - NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients Phase 1
Withdrawn NCT04011358 - Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study N/A
Completed NCT02898480 - Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning N/A
Recruiting NCT01581151 - Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion N/A
Completed NCT01428388 - Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion N/A
Completed NCT00970957 - Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Phase 3
Recruiting NCT04075695 - Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
Recruiting NCT03525132 - Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) N/A
Recruiting NCT03762226 - Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study
Recruiting NCT02257333 - Retinal Thrombosis and Atherosclerosis
Recruiting NCT04140448 - Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
Active, not recruiting NCT05003258 - Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection N/A
Terminated NCT04707625 - Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment Phase 4
Recruiting NCT04142164 - Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections N/A
Completed NCT02523339 - Study of Retinal Oxygenation in Central Retinal Vein Occlusion
Active, not recruiting NCT01449682 - Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. Phase 3
Completed NCT01568021 - Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1